NASDAQ: EIKN
Eikon Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for EIKN

Based on 5 analysts offering 12 month price targets for Eikon Therapeutics Inc

Min Forecast
$7.00-33.84%
Avg Forecast
$25.60+141.97%
Max Forecast
$34.00+221.36%

Should I buy or sell EIKN stock?

Based on 5 analysts offering ratings for Eikon Therapeutics Inc.

Buy
Strong Buy
3 analysts 60%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
1 analysts 20%
Strong Sell
0 analysts 0%
Although EIKN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates EIKN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their EIKN stock forecasts and price targets.

EIKN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-31
lockedlocked$00.00+00.00%2026-03-02
lockedlocked$00.00+00.00%2026-03-02
lockedlocked$00.00+00.00%2026-03-02
lockedlocked$00.00+00.00%2026-03-02

1 of 1

Forecast return on equity

Is EIKN forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is EIKN forecast to generate an efficient return on assets?

EIKN revenue forecast

What is EIKN's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

EIKN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EIKN$10.58$25.60+141.97%Buy
TECX$30.91$60.00+94.11%Strong Buy
ZURA$5.95$14.75+147.90%Strong Buy
MDXG$3.95$9.50+140.51%Strong Buy
OCGN$1.81$9.75+438.67%Strong Buy

Eikon Therapeutics Stock Forecast FAQ

Is Eikon Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: EIKN) stock is to Buy EIKN stock.

Out of 5 analysts, 3 (60%) are recommending EIKN as a Strong Buy, 1 (20%) are recommending EIKN as a Buy, 0 (0%) are recommending EIKN as a Hold, 1 (20%) are recommending EIKN as a Sell, and 0 (0%) are recommending EIKN as a Strong Sell.

If you're new to stock investing, here's how to buy Eikon Therapeutics stock.

What is EIKN's revenue growth forecast for 2026-2028?

(NASDAQ: EIKN) Eikon Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 54.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.22%.

Eikon Therapeutics's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast EIKN's revenue for 2026 to be $0, with the lowest EIKN revenue forecast at $0, and the highest EIKN revenue forecast at $0. On average, 5 Wall Street analysts forecast EIKN's revenue for 2027 to be $0, with the lowest EIKN revenue forecast at $0, and the highest EIKN revenue forecast at $0.

In 2028, EIKN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is EIKN's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: EIKN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9%.

What is EIKN's Price Target?

According to 5 Wall Street analysts that have issued a 1 year EIKN price target, the average EIKN price target is $25.60, with the highest EIKN stock price forecast at $34.00 and the lowest EIKN stock price forecast at $7.00.

On average, Wall Street analysts predict that Eikon Therapeutics's share price could reach $25.60 by Mar 31, 2027. The average Eikon Therapeutics stock price prediction forecasts a potential upside of 141.97% from the current EIKN share price of $10.58.

What is EIKN's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: EIKN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.